TrialInternational journal of clinical oncology2014

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).

Tadahiko Shien et al.PubMed ↗Publisher ↗

No numbers read from the abstract.